Generalized anxiety disorder: neurobiological and pharmacotherapeutic perspectives
- 1 December 1998
- journal article
- review article
- Published by Elsevier in Biological Psychiatry
- Vol. 44 (12) , 1286-1294
- https://doi.org/10.1016/s0006-3223(98)00285-6
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- A Double-Blind, Placebo-Controlled Study of a CCK-B Receptor Antagonist, CI-988, in Patients With Generalized Anxiety DisorderJournal of Clinical Psychopharmacology, 1995
- CSF serotonin: Diagnostic and seasonal differencesBiological Psychiatry, 1995
- The Concepts of Stress and Stress System DisordersJAMA, 1992
- Blunted Growth Hormone Response to Clonidine in Patients With Generalized Anxiety DisorderArchives of General Psychiatry, 1991
- Adrenergic status in anxiety disorders: Platelet alpha2-adrenergic receptor binding, blood pressure, pulse, and plasma catecholamines in panic and generalized anxiety disorders patients and in normal subjectsBiological Psychiatry, 1990
- The genetics of six neurotic disorders: a twin studyJournal of Affective Disorders, 1990
- The Diagnostic Utility of Lactate Sensitivity in Panic DisorderArchives of General Psychiatry, 1990
- Noradrenergic function in generalized anxiety disorder: Effects of yohimbine in healthy subjects and patients with generalized anxiety disorderPsychiatry Research, 1989
- Double-blind comparison of buspirone and clorazepate in anxious outpatientsThe American Journal of Medicine, 1986
- The DST in psychiatric outpatients with generalized anxiety disorder, panic disorder, or primary affective disorderAmerican Journal of Psychiatry, 1985